Ryght AI Announces New Partnerships and Funding to Digitize Every Clinical Trial Site with AI

Ryght AI, a leading provider of real-time generative AI solutions for the clinical research industry, today announced several new academic medical center (AMC) partnerships and a $3 million seed round led by Foothill Ventures. The company’s existing investors include AIX Ventures, Virtue Ventures, IASO Ventures, Top Harvest Capital, and Page One Ventures. The new partnerships with AMCs such as Emory University, West Virginia University, West Clinic, and three others join previously announced partners The University of Southern California Keck School of Medicine and the Medical College of Wisconsin. This rapid adoption underscores the platform’s “service as software” approach to the $140 billion, labor-intensive clinical trial services market which has also been popular with biotech and pharma sponsors and CROs.

Industry’s Problem: Manual and Broken Workflows Stall Drug Development

Today’s clinical trials remain hamstrung by siloed data and manual processes. Sponsors and CROs spend up to $50,000 activating a single site and $50,000–$500,000 enrolling each patient. Despite this massive investment, 55 percent of trials still fail due to poor site feasibility, slow activation, and the mismatch between site capabilities and trials’ needs. Identifying ideal sites is often guesswork, budget negotiations drag on for weeks, and sites are overwhelmed by redundant forms, all contributing to massive cost overruns, delayed therapies, and frustrated investigators.

“Ryght AI has transformed how we approach site identification, selection and activation in our clinical trials,” said Dr. Timothy Sirard, Global Head of Feasibility and Senior Director for Clinical Business Development, QPS. “The way that most in the industry identify sites for trial activation and enrollment typically involves downloading spreadsheets of site data from various data vendors with old and inaccurate information, poring over the data to identify investigators and sites that might fit a specific trial, then reaching out to those sites with depressingly low response rates. For QPS, what used to take weeks of back-and-forth can now happen in days, and our teams instead focus on efficiently activating sites that we know are high quality, provide access to the patients and will successfully enroll – across all geographies. Ryght is our go-to system for reliable site identification and feasibility that every biotech and pharma should demand be part of their site selection.”

Ryght AI’s Solution: Agentic AI and a Global Digital-Twin Network

Ryght AI solves these bottlenecks with a generative- and agentic-AI-native platform by building a live “digital twin” profile for every clinical research site in the world, now over 100,000 worldwide. Enabling AI-recommended, data-driven site selection, automated feasibility, and rapid activation on a SOC 2-compliant AI platform and network, Ryght AI is building a real-time approach to synthetic outcome analysis, site identification, selection and activation.

By seamlessly integrating with sponsor, CRO, and site workflows, Ryght AI delivers a fully orchestrated, end-to-end agentic AI solution that saves months of admin work while autonomously connecting the very best sites globally to any trial protocol, then accelerating the site activation and patient enrollment. Behind the scenes, Ryght’s agent-driven apps tap into a live global network of over 100,000 “digital twin” site profiles to automatically understand and analyze complex trial protocols, connect them to the sites that will succeed, then speed contract completion and patient enrollment. The AI technology then allows research sites to rapidly identify eligible patients for available studies, thereby facilitating rapid and timely enrollment.

Key features include:

• Site Digital Twin: A virtual, AI assisted version of every site that automates the workflow for sites, sponsors and CROs to speed site selection and activation. Also allows sponsors to synthetically test protocol changes to predict downstream impacts on patient enrollment - across a global network of actual sites.
  
  
• Network Navigator: Effortlessly query Ryght’s Network of over 100,000+ digital twins to identify and match the best sites for any study - for new or rescue studies.
  
  
• Patient Pre-Screening: AI that allows sites to rapidly identify eligible patients for any open, recruiting study at the research site, eliminating manual work or unneeded EMR integrations.
  
• Protocol Adherence: For sites to manage patient visits and needed tests and treatments using AI to assure compliance with all complex protocol requirements, thereby mitigating errors and manual labor.
  
• AI Assisted Budgeting: Simply upload a trial’s schedule of events to auto-generate, negotiate, and finalize site budgets, compressing weeks of back-and-forth into minutes
• Medical Writing: Empower clinical and BD teams with AI assistants that draft informed consent forms, trial protocols, CRO proposals and other essential documents in a fraction of the time

“Our vision is to unite the world’s clinical trial sites into one intelligent, real-time ecosystem,” said Simon Arkell, Co-Founder & CEO, Ryght AI. “Through the use of agentic AI across a real-time global network, Ryght doesn’t just accelerate activation, it drives real-time collaboration between sponsors, their CROs and sites so breakthroughs reach patients faster than ever.”

“Ryght’s team has shown an incredible drive and understanding of the pain points in the clinical trial industry, as shown by their ability to sign eight premier AMCs and other commercial partnerships in such a short period of time,” said Lu Wang, Investment Director at Foothill Ventures. “We’re excited to back their quest to disrupt and improve this $140 billion industry.”

To learn more about partnership opportunities, please visit https://www.ryght.ai/.

About Ryght AI

Ryght AI is the first agentic-AI platform designed to automate every step of clinical trial site selection, activation, and enrollment. By combining generative-AI agents with a secure digital-twin network of over 100,000 trial sites, SOC 2 compliance, and integrated applications for sponsors, CROs, and research sites, Ryght delivers “service as software” that accelerates trials, reduces costs, and improves patient access to new therapies. Founded in 2024 and headquartered in Laguna Beach, California, Ryght AI is backed by Foothill Ventures, AIX Ventures, Virtue Ventures, IASO Ventures, Top Harvest Capital, Page One Ventures, and notable industry veterans. Learn more at www.ryght.ai.

Contact Information

Riley Munks

PR Advisor

Activate PR - https://www.activate-pr.com/

riley@activate-pr.com